Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Revenue Up At Allos, But Losses Continue

By R&D Editors | May 12, 2011

WESTMINSTER, Colo. (AP) – Shares of Allos Therapeutics Inc. fell after the company reported disappointing first-quarter sales results for its lymphoma drug Folotyn.

The stock dipped 34 cents, or 11.9 percent, to $2.51 in afternoon trading. Shares earlier reached $2.35, marking the lowest point in about five years.

The company said it lost $15.2 million, or 14 cents per share, compared with a loss of $20.5 million, or 20 cents per share, during the same period a year prior. Revenue rose 47 percent to $10.9 million from $7.4 million.

Folotyn is the company’s only marketed product.

Analysts surveyed by FactSet expected a loss of 15 cents per share on $12.2 million in revenue.

Looking ahead, the company said it expects sales between $48 million and $55 million in 2011. Analysts expect about $61.8 million in sales.

Meanwhile, the company signed a commercialization deal with Mundipharma for Folotyn. Under the deal, Mundipharma will have exclusive rights to the drug in all countries outside of the U.S. and Canada. Allos will receive an upfront payment of $50 million and potential regulatory and sales milestone payments of up to $310.5 million. Allos is also entitled to receive royalties based on sales.

Brean Murray, Carret & Co. analyst Brian Skorney reaffirmed a “Buy” rating, but reduced his price target to $6 from $9, saying the quarter “was a mixed bag” for the company.

While Folotyn sales were disappointing, he said, the company offset those results with a partnership deal that provides the company with an immediate cash infusion.

Related Articles Read More >

2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE